Comparison
Semaglutide vs Tirzepatide
Side-by-side attributes from our library comparison data. Read each peptide leaf for dosing math, regulatory status, and citations.
Semaglutide vs. Tirzepatide
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual receptor agonist |
| Peak Weight Loss | 14.9–17% body weight (STEP trials) | 22.5% body weight (SURMOUNT-1) |
| FDA Approval | Ozempic® (T2D) / Wegovy® (obesity) | Mounjaro® (T2D) / Zepbound® (obesity) |
| Half-Life | ~7 days (once weekly) | ~5 days (once weekly) |
| GI Side Effects | Moderate - nausea most common | Similar profile; slightly more at peak dose |
| Starting Dose | 0.25 mg/week (escalated over 20 wks) | 2.5 mg/week (escalated over 20 wks) |
| Cost (branded) | ~$900–1,100/mo list price | ~$1,000–1,200/mo list price |
Verdict: Tirzepatide delivers greater weight loss due to its dual receptor mechanism; semaglutide has a longer clinical track record and broader global availability. For maximum weight loss, tirzepatide is the better choice; for established safety data, semaglutide leads.